Choosing an Atypical Antipsychotic for Acute Mania Against a New Metabolic Finding
A single patient, two days into an involuntary hold for his first manic episode. Several atypical antipsychotics have real acute-mania efficacy, but a newly discovered prediabetic lab value changes which one's metabolic cost is acceptable tonight.
W.H. is a 45-year-old man, father of two young children under five, who works night shifts as a 911 dispatcher. He was brought to the emergency department by police two days ago after neighbors reported him directing traffic in the street at 2 a.m., convinced he had been recruited for a classified government project. He has no prior psychiatric diagnosis, though his wife says he had gone almost a week without real sleep beforehand, working overtime shifts and staying up afterward to 'finish planning.' He is now on an involuntary psychiatric hold, floridly manic — grandiose, pressured, sleeping perhaps two hours a night, and intermittently agitated enough that staff have twice had to redirect him from approaching other patients on the unit.
Admission labs, drawn partly because he mentioned his father has type 2 diabetes, came back with a hemoglobin A1c of 6.2% — prediabetic range, previously undiagnosed. That finding matters directly for tonight's decision, because several atypical antipsychotics carry genuine acute-mania efficacy with meaningfully different metabolic costs: olanzapine has among the strongest and fastest antimanic effect sizes but also the highest metabolic burden of the group, which is a harder trade to accept in a patient who just crossed into prediabetes than it would be in a metabolically healthy one. Risperidone and quetiapine both have solid acute-mania evidence with comparatively less metabolic risk, but neither controls agitation quite as fast, and he is agitated enough tonight that speed is not a trivial consideration either. His wife, sitting in the family room down the hall, keeps asking when he'll be well enough to see their children again — a question nobody on the team can answer yet, but one that makes clear how much is riding on getting tonight's choice right the first time rather than cycling through agents while he stays acutely unwell.
At the bedside, hospital day 2
He has redirected toward other patients twice tonight, which puts real weight on rapid control, and olanzapine's antimanic effect is both fast and well-established. I don't think a single hemoglobin A1c of 6.2% should override the acute safety picture on the unit right now.
Risperidone's onset for behavioral control isn't meaningfully slower than olanzapine's in the trial data, and it carries a real metabolic advantage in a patient who just crossed into prediabetes at 45 — this isn't someone we're protecting hypothetically, the lab result is already abnormal today.
If he were floridly agitated to the point of requiring an IM option right this hour, I'd weigh this differently. He's redirectable, not requiring restraint — that's the distinction that lets metabolic risk carry real weight in tonight's choice.
From the medical side: an A1c of 6.2% is prediabetes, not diabetes, and it is reversible with the right choices now. Starting him on the antipsychotic with the highest metabolic burden of the group, even for what everyone plans to be a short acute course, is exactly the kind of exposure that turns a reversible finding into a permanent one, especially if the "short course" runs longer than planned, which happens more often than not.
Risperidone started at 2mg twice daily with lorazepam available as needed for breakthrough agitation. Endocrinology and nutrition consults placed for his newly identified prediabetes, with a plan to recheck metabolic labs regardless of which antipsychotic he ultimately continues on after discharge.
The disagreement about how much weight one abnormal lab value should carry against the urgency of his agitation was not fully resolved — the attending's concern that risperidone might prove too slow if his behavior escalates further was documented explicitly, with a standing order to reconsider olanzapine if agitation worsens materially rather than assuming risperidone would hold.